Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection-Reference-Cited by-同舟云学术

Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection

Published:2021 Issue: Volume:23 Page:e01041
ISSN:2214-2509
Container-title:IDCases
language:en
Short-container-title:IDCases

Author:

Ahmad Alhiyari Mousa^ORCID,Ata Fateen^ORCID,Islam Alghizzawi Mohd^ORCID,Bint I Bilal Ammara^ORCID,Salih Abdulhadi Ahmad,Yousaf Zohaib^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference19 articles.

1. Coronavirus disease (COVID-19) Data as received by WHO from national authorities, as of 27 September 2020, 10 am CEST. Global epidemiological situation;WHO,2020

2. Post COVID -19 pneumonia pulmonary fibrosis;Tale;QJM,2020

3. Pulmonary fibrosis in the aftermath of the COVID-19 era (Review);Vasarmidi;Exp Ther Med,2020

4. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy;George;Lancet Respir Med,2020

5. The COVID-19 epidemic;Velavan;Trop Med Int Health,2020

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative phytoceutical-based drug delivery in the management of pulmonary fibrosis: A roadmap towards inhaled therapeutics;Journal of Drug Delivery Science and Technology;2024-09

2. Corrigendum to “Decomposing neighborhood disparities in bicycle crashes: A Gelbach decomposition analysis” [Transport Pol. 131 (2023) 156–172];Transport Policy;2024-02

3. A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection;Frontiers in Immunology;2023-10-02

4. The Effect of Potassium Canrenoate (Mineralocorticoid Receptor Antagonist) on the Markers of Inflammation in the Treatment of COVID-19 Pneumonia and Fibrosis—A Secondary Analysis of Randomized Placebo-Controlled Clinical Trial;International Journal of Molecular Sciences;2023-09-18

5. Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects;Journal of Nanobiotechnology;2023-07-08